For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

BPC-157

Also known as: Body Protection Compound 157, PL 14736

Research use only · not FDA-approved

Pentadecapeptide derived from a gastric protective protein. Studied for tendon/ligament healing, GI tract repair, and angiogenesis via VEGFR2 pathway interaction.

Where to buy · live market data

Who's worth your money for BPC-157

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 46 scored sellers

$1.00/mg

$800 · 800mg · 99.8% purity

Best value after code

$0.59/mg effective with 10% code

$0.66/mg

$19.75 · 30mg

no COAs yet
Buy Code merit · 10% off

Most tested

93 independent COAs on file

$5.30/mg

$53.00 · 10mg · 99.7% purity

Average price

$5.44/mg

Sellers

83

45-day trend

-40.5%

71 of 83 sellers have a current price· 4 stale hidden· 21 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch BPC-157

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About BPC-157

CAS

137525-51-0

Molecular formula

C62H98N16O22

Sequence

GEPPPGKPADDAGLV

Typical dose range

200-500 mcg/day subcutaneous or intramuscular

Half-life

<30 minutes (IV: ~15 min in rats, ~5 min in dogs)

Common research uses

tendon and ligament injury recoverygastrointestinal ulcer healing (animal studies)post-surgical recovery (research only)

Safety notes

Not FDA-approved for human therapeutic use. WADA does not currently prohibit BPC-157 but research-use only status applies in most jurisdictions.

Reconstitution

Reconstitute lyophilized powder with bacteriostatic water; refrigerate after reconstitution.

Independent evidence

COAs for BPC-157

555 third-party tests across 60 vendors. Each card links to the full report.

All 555 COAs for BPC-157 →
Measured purity 76.3%–100.0% across 345 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.73 %
Sep 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch bpc10-10

Aggregated · 3rd-party listing
99.83 %
Sep 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BC10-11

Aggregated · 3rd-party listing
99.94 %
Sep 2026
Janoshik Analytical Limited

For

BPC-157

by CertaPeptides· batch CP-2608-BPC10-B

Aggregated · 3rd-party listing
99.43 %
Sep 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC20-07

Aggregated · 3rd-party listing
99.16 %
Sep 2026
Freedom Diagnostics Moderate

For

BPC-157

by Forge Performance Co.· batch BPC15720-2609-01-PUR-SLV

Aggregated · 3rd-party listing
99.22 %
Aug 2026
Freedom Diagnostics Moderate

For

BPC-157

by VoriLabs· batch BPV-2608-B

Aggregated · 3rd-party listing
99.59 %
Aug 2026
ILS Labs Strong

For

BPC-157

by Arctic Lab supply· batch BCP-2502-B

Aggregated · 3rd-party listing
99.88 %
Aug 2026
ILS Labs Strong

For

BPC-157

by Velora Biolabs· batch VBL-BC10-1

Aggregated · 3rd-party listing
98.35 %
Aug 2026
Freedom Diagnostics Moderate

For

BPC-157

by Synthesis Peptides· batch BPC10926A

Aggregated · 3rd-party listing
99.69 %
Jul 2026
ILS Labs Strong

For

BPC-157

by NovaForge Labs· batch Lot - 2026 - 1

Aggregated · 3rd-party listing
99.79 %
Jul 2026
ILS Labs Strong

For

BPC-157

by jdbioworks· batch 2026-002

Aggregated · 3rd-party listing
99.72 %
Jul 2026
ILS Labs Strong

For

BPC-157

by Voltera Sciences· batch BC10-07082026

Aggregated · 3rd-party listing
99.86 %
Jul 2026
ILS Labs Strong

For

BPC-157

by Artisan Aminos· batch AA-BP10-049

Aggregated · 3rd-party listing
99.62 %
Jul 2026
Janoshik Analytical Limited

For

BPC-157

by CertaPeptides· batch CP-2604-BC20

Aggregated · 3rd-party listing
99.56 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch 161-620L-DK

Aggregated · 3rd-party listing
99.44 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Synthesis Peptides· batch BPC10826

Aggregated · 3rd-party listing
99.90 %
Jul 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC10-08

Aggregated · 3rd-party listing
99.42 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Modern Research Peptides· batch EV24338MON

Aggregated · 3rd-party listing
99.00 %
Jul 2026
Ethos Analytics Strong

For

BPC-157

by OROS Research· batch OR-LPBPC5-626-B6

Aggregated · 3rd-party listing
99.91 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch 148-01-DK

✓ Vendor-published
99.51 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Ion Peptide· batch BCS-06242026

COA on file
Aggregated · 3rd-party listing
99.91 %
Jun 2026
ILS Labs Strong

For

BPC-157

by Orbitrex Peptides· batch BPC10726US

Aggregated · 3rd-party listing
99.51 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Ion Peptide· batch BC5-06242026

Aggregated · 3rd-party listing
99.64 %
Jun 2026
Janoshik Analytical Limited

For

BPC-157

by Optima Supply· batch OS-2026-3074

Research depth

21 citations indexed for BPC-157

All research on BPC-157 →

rct · Ongoing

Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery

This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR).

review · 2026

BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence

Ischemia-reperfusion injury (IRI) is a clinically important consequence of blood-flow restoration after ischemia and contributes to tissue damage across multiple organ systems.

Study · 2026

Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel

Multifunctional hydrogels are essential for advanced biomedical applications. In this study, CH/BPC composite hydrogel was fabricated and characterized for their physicochemical properties.

Study · 2026

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase

Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer's disease.

animal · 2026

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

Objectives This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model.

animal · 2026

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach

Background . This rat study reveals a new point: the considerable impact of unilateral adrenalectomy, severe vascular and multiorgan failure, occlusion/occlusion-like syndrome, and the stable gastric pentadecapeptide BPC 157 therapy.

Research use only. Not for human consumption and not approved by the FDA.